Erschienen in:

01.02.2009 | Original Article

Moderate risk-adapted dose escalation with three-dimensional conformal radiotherapy of localized prostate cancer from 70 to 74 Gy

First report on 5-year morbidity and biochemical control from a prospective Austrian-German multicenter phase II trial

verfasst von: Gregor Goldner, MD, Valentin Bombosch, Hans Geinitz, Gerd Becker, Stefan Wachter, Stefan Glocker, Frank Zimmermann, Natascha Wachter-Gerstner, Andrea Schrott, Michael Bamberg, Michael Molls, Horst Feldmann, Richard Pötter

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 2/2009